Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jack Callicutt Insider Profile
4 Followers
Jack Callicutt, CFO at Galectin Therapeutics, holds 7.61K shares in Galectin Therapeutics (Ticker: GALT). Most recently, Jack Callicutt Bought $4,000 shares of Galectin Therapeutics on Nov 17, 2022 for an estimated value of 5.28K.
Profitable Transactions
2 out of 4 Profitable Transactions
Average Return
+4.00%
Average return per transaction
Time Frame
Compare to
Insider Roles
CFO
Roles that Jack Callicutt holds in companies
Most Profitable Insider Trade
Stock:
Rating:Informative Sell
Date:Jun 21, 2018 - Jun 21, 2019
Return:+49.20%
The most profitable trade made by Jack Callicutt
Jack Callicutt's Trading History
List of latest transactions for each holding click on a transaction to see Jack Callicutt's performance on stock
You May Also Like
Jack Callicutt insider profile FAQ
What is the percentage of profitable transactions made by Jack Callicutt?
The percentage of profitable transactions made by Jack Callicutt is 50%.
What is the average return per transaction made by Jack Callicutt?
The average return per transaction made by Jack Callicutt is 4.00%.
What stocks does Jack Callicutt hold?
Jack Callicutt holds: GALT stocks.
What was Jack Callicutt’s latest transaction?
Jack Callicutt latest transaction was an Informative Buy of $5.28K.
What was Jack Callicutt's most profitable transaction?
Jack Callicutt’s most profitable transaction was an Informative Sell of GALT stock on June 21, 2018. The return on the trade was 49.20%.
What is Jack Callicutt's role in Galectin Therapeutics?
Jack Callicutt's role in Galectin Therapeutics is CFO.
How can I follow the stock ratings of top corporate insiders?
Head over to our Expert Center to see a list of the Top 100 corporate insiders and follow the corporate insiders of your choice. Visit their profiles for more details about their stock transactions and see how they perform on a stock-by-stock basis.